Stock Research for TTPH


Featured Broker: Ally Invest

Get the due diligence for another stock.


TTPH Stock Chart & Research Data

The TTPH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TTPH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


TTPH Due diligence Resources & Stock Charts

The TTPH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View TTPH Detailed Price Forecast - CNN Money CNN View TTPH Detailed Summary - Google Finance
Yahoo View TTPH Detailed Summary - Yahoo! Finance Zacks View TTPH Stock Research & Analysis -

Stock Analysis

TradeIdeas View TTPH Trends & Analysis - Trade-Ideas Barrons View TTPH Major Holders - Barrons
NASDAQ View TTPH Call Transcripts - NASDAQ Seeking View TTPH Breaking News & Analysis - Seeking Alpha
Spotlight View TTPH Annual Report - OTC Report View TTPH OTC Short Report -
TradeKing View TTPH Fundamentals - TradeKing Charts View TTPH SEC Filings - Bar Chart
WSJ View Historical Prices for TTPH - The WSJ Morningstar View Performance/Total Return for TTPH - Morningstar
MarketWatch View the Analyst Estimates for TTPH - MarketWatch CNBC View the Earnings History for TTPH - CNBC
StockMarketWatch View the TTPH Earnings - StockMarketWatch MacroAxis View TTPH Buy or Sell Recommendations - MacroAxis
Bullish View the TTPH Bullish Patterns - American Bulls Short Pains View TTPH Short Pain Metrics -

Social Media Mentions

StockTwits View TTPH Stock Mentions - StockTwits PennyStocks View TTPH Stock Mentions - PennyStockTweets
Twitter View TTPH Stock Mentions - Twitter Invest Hub View TTPH Investment Forum News - Investor Hub
Yahoo View TTPH Stock Mentions - Yahoo! Message Board Seeking Alpha View TTPH Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for TTPH - Insider Cow View Insider Transactions for TTPH - Insider Cow
CNBC View TTPH Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for TTPH - OTC Markets
Yahoo View Insider Transactions for TTPH - Yahoo! Finance NASDAQ View Institutional Holdings for TTPH - NASDAQ

Stock Charts

FinViz View TTPH Stock Insight & Charts - StockCharts View TTPH Investment Charts -
BarChart View TTPH Stock Overview & Charts - BarChart Trading View View TTPH User Generated Charts - Trading View

Latest Financial News for TTPH

Analysts’ Ratings for Sarepta Therapeutics and Peers in April
Posted on Friday April 20, 2018

How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapy, and other genetic approaches for treating rare neuromuscular diseases. Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and two analysts gave it a “hold” rating.

Tetraphase Pharmaceuticals’ Cash Flow and Price Performance
Posted on Thursday April 19, 2018

Tetraphase Pharmaceuticals (TTPH) posted $98.0 million in operating expenses in fiscal 2017, compared with $63.7 million in fiscal 2016. This $34.3 million rise resulted from increased expenses related to the company’s eravacycline Phase 3 studies. Other primary factors included higher drug manufacturing and nonclinical costs in support of its New Drug Application (or NDA) and precommercialization activities for eravacycline.

Tetraphase Pharmaceuticals to Present Data at the 38th Annual Meeting of the Surgical Infection Society
Posted on Thursday April 19, 2018

Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced two data presentations at the 38th Annual Meeting of the Surgical Infection Society (SIS), taking place April 22-25, at the Four Seasons in Westlake Village, CA. Presentations will include information about the Company’s lead drug candidate, eravacycline, which is in development for the treatment of complicated intra-abdominal infections (cIAI). “Data presented at SIS’s Annual Meeting demonstrate eravacycline’s potent in vitro activity from a total of 7,815 single-patient clinical isolates collected during a four-year period from U.S. hospitals,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase Pharmaceuticals.

Exploring Tetraphase Pharmaceuticals’ Financial Performance
Posted on Wednesday April 18, 2018

Tetraphase Pharmaceuticals (TTPH) generated contract and grant revenues of $9.6 million in fiscal 2017 compared with $5.1 million in fiscal 2016. Until now, the primary source of revenues for the company has been US government contracts. 

Enter a stock symbol to view the stock details.